Ralliant (NYSE:RAL) Director Purchases $99,828.00 in Stock

Ralliant Corporation (NYSE:RAL) Director Kate Mitchell purchased 2,350 shares of the business’s stock in a transaction on Tuesday, February 10th. The stock was acquired at an average price of $42.48 per share, with a total value of $99,828.00. Following the purchase, the director directly owned 8,411 shares in the company, valued at $357,299.28. This represents a 38.77% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ralliant Price Performance

Shares of RAL stock traded down $0.05 on Thursday, reaching $42.68. The company’s stock had a trading volume of 2,273,328 shares, compared to its average volume of 2,097,411. The company has a market capitalization of $4.81 billion and a price-to-earnings ratio of 21.78. Ralliant Corporation has a 1 year low of $37.27 and a 1 year high of $57.02. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.38. The stock’s fifty day simple moving average is $51.11 and its 200-day simple moving average is $46.62.

Ralliant (NYSE:RAL) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.67 by $0.02. The firm had revenue of $554.60 million for the quarter, compared to analysts’ expectations of $543.04 million. The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, March 23rd. Investors of record on Monday, March 9th will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 9th. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Ralliant’s dividend payout ratio is presently 10.20%.

Trending Headlines about Ralliant

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Director insider purchase — Ralliant director Anelise Angelino Sacks bought 2,000 shares (~$82.5k), a signal of management confidence that can reassure some investors. Article Title
• Positive Sentiment: Investor outreach scheduled — CEO and CFO will present at Citi and Barclays investor conferences next week, offering management a forum to explain the impairment, guidance and recovery plan. Article Title
• Neutral Sentiment: Analyst target trims but mixed ratings — several banks cut price targets (e.g., Barclays, Citi, Oppenheimer lowered targets) which reduces near‑term enthusiasm even where coverage remains constructive. Article Title
• Negative Sentiment: Large non‑cash goodwill impairment and lowered guidance — the company disclosed a sizable ($~1.4B) impairment in its Test & Measurement segment and cut FY2026 outlook, a material hit to fundamentals that drove major analyst re‑ratings. Article Title
• Negative Sentiment: Multiple shareholder/law‑firm investigations — several firms (Levi & Korsinsky, Kessler Topaz, Block & Leviton, Kaplan Fox and others) are probing whether Ralliant adequately disclosed headwinds and the timing of the impairment and guidance — raises litigation, regulatory and reputational risk. Article Title
• Negative Sentiment: Market reaction and short interest — shares plunged sharply on the disclosure and short interest spiked (~58.7% increase in January to ~3.75M shares), which can amplify downside volatility. Article Title
• Negative Sentiment: Additional analyst downgrades — some shops (e.g., Zacks) moved to more negative ratings, increasing selling pressure and reducing short‑term investor appetite. Article Title

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Zacks Research downgraded shares of Ralliant from a “hold” rating to a “strong sell” rating in a report on Monday. Truist Financial cut their target price on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Weiss Ratings cut shares of Ralliant from a “hold (c)” rating to a “sell (d)” rating in a research note on Thursday, February 5th. Citigroup reduced their price objective on Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Finally, Vertical Research upgraded shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a report on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $50.50.

Institutional Investors Weigh In On Ralliant

Several hedge funds have recently made changes to their positions in the business. Dodge & Cox acquired a new stake in Ralliant in the second quarter valued at $523,571,000. Viking Global Investors LP acquired a new position in shares of Ralliant during the 2nd quarter valued at about $257,200,000. State Street Corp acquired a new stake in Ralliant in the second quarter valued at approximately $213,096,000. Flossbach Von Storch SE purchased a new position in Ralliant in the 2nd quarter valued at about $198,077,000. Finally, Norges Bank acquired a new stake in Ralliant during the 4th quarter valued at approximately $124,687,000.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.